Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with hepatocellular carcinoma (liver cancer) confirmed by a scan, tissue sample, or cell sample
- People whose liver cancer is at an advanced stage (BCLC Stage C) and has spread to areas outside the liver
- People who have not previously received any systemic (whole-body) treatments for their liver cancer, such as chemotherapy, targeted therapy, or immunotherapy
- People who received a specific combination of treatments — an immune checkpoint drug (PD-1/PD-L1 inhibitor) and a drug that targets blood vessel growth (anti-angiogenic drug) — where both drugs are approved and available on the market, even if not specifically approved for liver cancer
- People who underwent a procedure called TACE (a treatment delivered directly to the liver through blood vessels) either within 3 months before starting the drug combination, or after starting it
- People who received at least one full round of the immune checkpoint and anti-angiogenic drug combination therapy after having TACE
- People who have measurable liver tumours that can be tracked over time
Who may not be able to join:
- People whose liver cancer is a specific less common type, such as cholangiocarcinoma, fibrolamellar, sarcomatoid hepatocellular carcinoma, or a mixed liver/bile duct cancer subtype — confirmed by tissue or pathology testing
- People whose treatment history does not fit the required combination and timing described above
- People with severely reduced liver function (Child-Pugh class C), a performance status score above 2 (meaning limited ability to carry out daily activities), or severe brain complications related to liver disease (hepatic encephalopathy)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Gao-jun Teng, M.D, Zhongda hospital, Southeast university, Nanjing, China
Phone: +86-02583272121
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Overall Survival(OS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.